Evento

Blocking soluble TNF to Improve potency of trastuzumab deruxtecan by increasing internalization and antitumor innate immune response in a resistant HER2-positive breast cancer model

Bruni, SofiaIcon ; Mauro, Florencia LucianaIcon ; Naveiro, Sofía; Cordo Russo, Rosalia InesIcon ; Dupont, Agustina; Mercogliano, María FlorenciaIcon ; Schillaci, RoxanaIcon
Tipo del evento: Simposio
Nombre del evento: San Antonio Breast Cancer Symposium
Fecha del evento: 05/12/2023
Institución Organizadora: American Association for Cancer Research;
Título de la revista: Cancer Research
Editorial: American Association for Cancer Research
ISSN: 0008-5472
e-ISSN: 1538-7445
Idioma: Inglés
Clasificación temática:

Resumen

Trastuzumab deruxtecan (T-DXd) administration provides a durable response for patients with HER2-positive and HER2 low metastatic breast cancer (BC) which resulted in its FDA approval.
Palabras clave: TRASTUZUMAB DERUXTECAN , HER2+ BREAST CANCER , TNF
 
Archivos asociados
Thumbnail
 
Tamaño: 471.5Kb
Formato: PDF
.
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/264974
URL: https://aacrjournals.org/cancerres/article/84/9_Supplement/PO2-18-05/744319/Abst
DOI: http://dx.doi.org/10.1158/1538-7445.SABCS23-PO2-18-05
Colecciones
Eventos(IBYME)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Blocking soluble TNF to Improve potency of trastuzumab deruxtecan by increasing internalization and antitumor innate immune response in a resistant HER2-positive breast cancer model; San Antonio Breast Cancer Symposium; San Antonio; Estados Unidos; 2023; PO2-18-05
Compartir
Altmétricas